OncRef
Skip to newsletter content
|
Breast cancerOctober 2026
0:00 / 3:25
Breast Cancer — Monthly Compass
Oct 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in breast cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
breast cancer updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • On October 7, 2026, the FDA approved tucatinib with trastuzumab and pertuzumab as a chemotherapy‑free front‑line maintenance regimen for adults with unresectable locally advanced or metastatic HER2‑positive breast cancer following induction therapy, supported by HER2CLIMB‑05 data.
    • On September 4, 2026, the FDA granted accelerated approval to camizestrant (Etcamah) plus a CDK4/6 inhibitor for ESR1‑mutated, HR+/HER2‑ advanced or metastatic breast cancer detected by ctDNA during first‑line therapy, as detailed in an October 12 explainer.
  • Important Drug Publication Updates
    • On October 1, 2026, The New England Journal of Medicine published evERA Phase III results showing that giredestrant plus everolimus significantly improved progression‑free survival in ER‑positive advanced breast cancer.
  • Key Clinical Development Updates
    • The FDA accepted Roche’s NDAs for giredestrant with a Priority Review for adjuvant early‑stage ER+/HER2− breast cancer (PDUFA November 30, 2026) and a standard review for advanced ESR1‑mutated ER+/HER2− disease (PDUFA December 18, 2026), with the advanced‑disease filing linked to evERA data.
    • The FDA cleared the IND for Prelude Therapeutics’ PRT13722, an oral KAT6A selective degrader, enabling a Phase 1 HR+/HER2− breast cancer trial to begin enrolling in Q4 2026 under a clinical collaboration with Lilly.
  • Important Clinical Trial Publications
    • In Annals of Oncology (October 24, 2026), the FOURLIGHT‑1 trial showed atirmociclib plus fulvestrant improved progression‑free survival versus fulvestrant or everolimus/exemestane in HR+/HER2− advanced breast cancer after CDK4/6 inhibitor exposure.
    • VIKTORIA‑1 late‑breaking results presented via ESMO slides reported that gedatolisib plus fulvestrant ± palbociclib achieved broad progression‑free survival gains over alpelisib‑based therapy across molecular subsets.
  • Key Conference Updates
    • At ESMO 2026 (Madrid; October 23–27), multiple late‑breaking phase 3 readouts showed topoisomerase‑I payload ADCs targeting HER2/TROP2 and a dual EGFR×HER3 bispecific ADC (izalontamab brengitecan) delivering consistent progression‑free survival gains versus chemotherapy across HER2‑low and HR+/HER2− metastatic populations while overall survival matures.
    • In the neoadjuvant TALENT study (LBA23), trastuzumab deruxtecan produced single‑digit pCR rates in HR+/HER2‑low early breast cancer with only marginal improvements from adding endocrine therapy or sequencing with TC chemotherapy, tempering immediate curative‑intent adoption.
  • Emerging Themes & Macro-Trends
    • Portfolio value is concentrating around ADC differentiation (payloads/targets and CNS activity), ER/PI3K combination blueprints, and companion liquid biopsy solutions, with cross‑modality partnerships such as pumitamig plus sacituzumab govitecan signaling convergence.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-10-01 and 2026-10-31 about breast cancer.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • FDA approved tucatinib (Tukysa, Seagen/Pfizer) with trastuzumab and pertuzumab as maintenance therapy for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. The decision establishes a front-line maintenance option for HER2+ metastatic disease. ¹ (read more)
  • Pfizer announced FDA approval of its TUKYSA-based regimen with trastuzumab and pertuzumab as a chemotherapy-free, front-line maintenance treatment for HER2+ metastatic breast cancer after induction therapy. The company highlighted HER2CLIMB-05 data as the basis for the approval. ² (read more)
  • Targeted Oncology reported the FDA’s October 7, 2026 approval of tucatinib plus trastuzumab and pertuzumab for HER2+ metastatic breast cancer maintenance. The article summarized HER2CLIMB-05 outcomes supporting the decision. ³ (read more)
  • Prelude Therapeutics announced a clinical trial collaboration with Lilly and stated that FDA recently cleared the IND for PRT13722, an oral KAT6A selective degrader, enabling a Phase 1 trial in HR+/HER2- breast cancer to begin enrolling in Q4 2026. The update links the IND clearance directly to the planned first-in-human study. ⁴ (read more)
  • Roche reported evERA Phase III results and confirmed that FDA accepted its NDAs for giredestrant: Priority Review for adjuvant early-stage ER+/HER2- breast cancer (PDUFA November 30, 2026) and standard review for advanced ESR1-mutated ER+/HER2- disease (PDUFA December 18, 2026). The release ties the advanced-disease filing to evERA data. ⁵ (read more)
  • Targeted Oncology covered evERA in an October 1 news article and noted FDA acceptance of the giredestrant NDAs with PDUFA goal dates of November 30, 2026 (adjuvant) and December 18, 2026 (advanced). The piece places the filings in context of giredestrant’s broader development program. ⁶ (read more)
  • In its October 22 ad hoc investor update, Roche reiterated giredestrant’s FDA PDUFA goal dates (November 30, 2026 in early-stage, December 18, 2026 in advanced ESR1-mutated disease). The update anchors these regulatory milestones within the company’s Q3 portfolio highlights. ⁷ (read more)
  • The Los Angeles Times published an explainer detailing the FDA’s September 4, 2026 accelerated approval of AstraZeneca’s camizestrant (Etcamah) plus a CDK4/6 inhibitor for ESR1‑mutated, HR+/HER2‑ advanced or metastatic breast cancer detected by ctDNA during first‑line therapy. The article reviews SERENA‑6 data, ODAC context, and key labeling elements. ⁸ (read more)
  • BriaCell announced an ESMO 2026 poster in metastatic breast cancer and reiterated that its Bria‑IMT combination regimen and pivotal Phase 3 program are under FDA Fast Track designation. The company highlighted ongoing clinical development under the expedited pathway. ⁹ (read more)
  • Pharmacy Times’ October oncology roundup recapped the FDA approval of tucatinib with trastuzumab and pertuzumab for HER2+ breast cancer maintenance. The article summarized efficacy data and practical considerations for implementation. ¹⁰ (read more)
Conference
Major Conference Updates
Conference Information
  • ESMO Congress 2026, Madrid, Spain; October 23–27, 2026
  • Sentiment: Metastatic breast cancer is being rapidly resegmented by ADCs while post‑CDK4/6 strategies and ctDNA tools refine personalization; early-disease ADC signals urge disciplined trial design before moving ADCs into curative settings. (read more)
  • Theme 1: ADCs Reshape Metastatic HR+/HER2− and HER2‑low Disease
    • Significance: Multiple late-breaking phase 3 readouts position ADCs as contenders to displace chemotherapy and extend benefit beyond HER2‑positive disease. (read more)
    • Mechanism insights / clinical impact: Topoisomerase‑I payload ADCs against HER2/TROP2 and a dual EGFR×HER3 bispecific ADC (“izalontamab brengitecan [iza‑bren]”) delivered consistent PFS gains vs chemotherapy; class activity remains strong while OS matures. Company lineups underscore depth (DESTINY‑Breast05/06/09/11; TROPION‑Breast02). (read more)
    • Patient populations affected: HER2‑low and HR+/HER2− metastatic populations across first and later lines; prior endocrine and chemotherapy‑exposed cohorts show pronounced benefit signals, with bispecific ADCs broadening targetable biology. (read more)
  • Theme 2: Early‑Setting ADCs—Proceed With Caution
    • Significance: Neoadjuvant “lift and shift” of metastatic ADC wins did not translate into robust pCR in HR+/HER2‑low early breast cancer, tempering enthusiasm for immediate curative‑intent use. (read more)
    • Mechanism insights / clinical impact: In TALENT (LBA23), trastuzumab deruxtecan (T‑DXd/trastuzumab deruxtecan‑nxki) yielded single‑digit pCR despite radiologic activity; adding endocrine therapy or sequencing with TC chemotherapy offered marginal pCR gains—highlighting biological and microenvironmental differences in EBC. (read more)
    • Patient populations affected: HR+/HER2‑low stage II–III candidates for neoadjuvant therapy; signals argue for biomarker‑enriched strategies and combination hypotheses before standard‑of‑care displacement. (read more)
  • Theme 3: Restoring Endocrine Sensitivity Post‑CDK4/6
    • Significance: Multiple datasets reinforce a pivot from “more chemo” to pathway‑precise regimens after CDK4/6i, aiming to prolong endocrine benefit and delay cytotoxic switches. (read more)
    • Mechanism insights / clinical impact: Atirmociclib (selective CDK4) + fulvestrant improved PFS vs fulvestrant or everolimus/exemestane in FOURLIGHT‑1; gedatolisib (pan‑PI3K/mTOR) + fulvestrant ± palbociclib in VIKTORIA‑1 showed broad PFS gains over alpelisib; ER‑targeting plus PI3Kα (giredestrant + inavolisib; MORPHEUS) advances combination rationales. (read more)
    • Patient populations affected: HR+/HER2− advanced breast cancer post‑CDK4/6i exposure (including PIK3CA‑mutant and wild‑type subsets), with potential to delay chemotherapy in global practice. (read more)
  • Theme 4: ctDNA‑Driven Response Assessment and Escalation Signals
    • Significance: Liquid biopsy is moving from research to decision‑support, enabling earlier response tracking and identifying high‑risk subgroups for adjuvant escalation. (read more)
    • Mechanism insights / clinical impact: DESTINY‑Breast06 ctDNA molecular response analyses and multiple MRD abstracts (e.g., ≥4 positive nodes enrich ER+/HER2− EBC for ctDNA‑guided escalation) highlight real‑time biology readouts aligned with ADC/endocrine strategies. (read more)
    • Patient populations affected: HR+/HER2− early and metastatic disease, including HER2‑low subsets; broadening to biomarker‑defined groups across geographies where liquid biopsy access is expanding. (read more)
  • Significance
    • Expected clinical or translational readouts: Mature OS from late‑breaking ADC trials; additional subgroup and brain metastases analyses from DESTINY/TROPION programs; expanded ctDNA‑response correlations. (read more)
    • Regulatory or policy implications: Positive phase 3 ADC data (e.g., PANKU‑Breast01 with iza‑bren) could catalyze 2027 filings; payer interest in ctDNA‑guided escalation/de‑escalation frameworks likely to grow (inference). (read more)
    • Potential shifts in standard of care: ADCs challenging chemotherapy in first‑/second‑line HR+/HER2− and HER2‑low MBC; post‑CDK4/6 algorithms incorporating selective CDK4 and PI3K/mTOR combinations. (read more)
    • Strategic implications: Portfolio value concentrates around ADC differentiation (payloads/targets, CNS activity), combination blueprints (ER/PI3K), and companion liquid biopsy solutions; partnerships (e.g., pumitamig + sacituzumab govitecan) signal cross‑modality convergence. (read more)
Publications Related to Approved Drugs
Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial. The prespecified six-year analysis of the NATALEE trial showed that adjuvant ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) provides a statistically significant overall survival (OS) benefit compared to NSAI alone in patients with HR+/HER2- early breast cancer. These positive OS results, consistent with an increasing reduction in recurrence risk and no new safety signals, reinforce the clinical benefit of this combination in the adjuvant setting for this broad patient population. ()
New Publications Related to Drugs in Clinical Trial Development
PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer. Preclinical data show that the PARP1-selective inhibitor DSB1559 improved survival and enhanced antitumor immunity compared to olaparib in Brca1-associated TNBC models, suggesting a potential new therapeutic strategy with reduced toxicity. A structurally related compound, DSB2455, is now advancing into a phase Ia/Ib clinical trial. ()
Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study. The novel FRα-targeting antibody-drug conjugate Sofetabart mipitecan (Sofe-M) demonstrated durable clinical activity and a favorable tolerability profile in heavily pretreated high-grade ovarian cancer patients, irrespective of FRα expression level or prior mirvetuximab soravtansine-gynx treatment. Notably, Sofe-M did not cause keratopathy or high-grade neuropathy, supporting its advancement to a phase 3 trial at the 3 mg/kg dose. ()
Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer. In a phase 3 trial, the combination of anbenitamab, a HER2-targeted bispecific antibody, with albumin-bound docetaxel (HB1801) demonstrated significantly higher progression-free survival compared to the standard docetaxel, trastuzumab, and pertuzumab (THP) regimen in patients with HER2-positive advanced breast cancer. This positions the anbenitamab-based regimen as a potent new first-line treatment option in this setting. ()
Phase Ia Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure. The novel acylfulvene alkylator LP-184 (zirdafulven) was well tolerated in a phase Ia study for advanced malignancies, including recurrent glioblastoma. Pharmacokinetic modeling suggests that combining LP-184 with spironolactone, a brain-penetrant inhibitor of DNA repair, could enhance its cytotoxic effects in brain tumors, providing a clear strategy for a future phase Ib/IIa trial. ()
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors. The first-in-human dose-escalation trial of LP-184, a novel acylfulvene pro-drug, established a maximum tolerated dose of 0.49 mg/kg and demonstrated a favorable safety profile in patients with advanced refractory solid tumors. While the best response was stable disease, its tolerability supports further investigation, potentially in combination with other agents or in biomarker-selected populations. ()
Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial. The phase 3 HORIZON-Breast06 trial demonstrated that trastuzumab rezetecan (SHR-A1811) significantly prolonged progression-free survival compared to physician's choice of chemotherapy in patients with ERBB2-low advanced breast cancer. These results establish trastuzumab rezetecan as a potential new standard of care in this setting, showing consistent benefit across hormone receptor subgroups. ()
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. In the final analysis of the postMONARCH trial, abemaciclib plus fulvestrant showed a numerical improvement in median overall survival (32.1 vs. 24.6 months) compared to placebo plus fulvestrant in HR+/HER2- advanced breast cancer patients who progressed on a prior CDK4/6 inhibitor, although it did not reach statistical significance. The totality of evidence, including consistent benefits in PFS and other secondary endpoints, supports considering this combination as a viable treatment strategy in this setting. ()
Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer: The I-SPY2.2 Randomized Clinical Trial. In the I-SPY2.2 trial, the combination of rilvegostomig and trastuzumab-deruxtecan (RT-DXd) showed promising neoadjuvant activity in high-risk, ERBB2-negative early breast cancer, particularly in immune-positive tumors. This chemotherapy-sparing regimen allowed a significant portion of responding patients to avoid anthracyclines, highlighting a potential new treatment paradigm for biomarker-selected populations. ()
Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial. A secondary analysis of the I-SPY2 trial revealed that although younger women (≤45 years) with high-risk breast cancer were more likely to undergo mastectomy after neoadjuvant therapy, the extent of surgery was not associated with improved overall survival or locoregional recurrence. This finding challenges the notion that young age alone necessitates more aggressive surgical approaches following effective systemic treatment. ()
Selpercatinib in Pediatric and Adolescent Patients With <i>RET</i>-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study. The selective RET inhibitor selpercatinib demonstrated durable efficacy and a favorable safety profile in pediatric and adolescent patients with RET-altered thyroid cancers, with an objective response rate of 53% and a 24-month duration of response rate of 100%. These findings support the use of targeted RET inhibition as a standard approach for this younger patient population. ()
Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial. The phase 3 PANKU-Breast01 trial showed that izalontamab brengitecan (iza-bren), a first-in-class bispecific antibody-drug conjugate, significantly improved progression-free survival compared to chemotherapy (8.2 vs. 4.0 months) in heavily pretreated Chinese patients with HR+/HER2- breast cancer. These results suggest iza-bren could become a new treatment option for this patient population, warranting further evaluation in global studies. ()
Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study. In the KEYNOTE-B49 study, adding pembrolizumab to chemotherapy resulted in a statistically significant but modest improvement in progression-free survival for patients with PD-L1–positive (CPS ≥1) HR+/HER2- advanced breast cancer. However, this benefit did not translate into a significant improvement in overall survival, indicating that this combination may not be a transformative strategy for this patient population. ()
Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study. The phase 1/2 study of farletuzumab ecteribulin (FZEC) identified interstitial lung disease (ILD)/pneumonitis as a key toxicity, which could be mitigated by using fractionated dosing schedules. A regimen of 8 mg/m² on days 1, 8, and 15 showed preliminary antitumor activity with no observed ILD, guiding the design for further dose optimization studies. ()
Giredestrant plus Everolimus in Advanced Breast Cancer. The phase 3 evERA trial demonstrated that the all-oral combination of giredestrant and everolimus significantly prolonged progression-free survival compared to standard endocrine therapy plus everolimus in patients with ER-positive, HER2-negative advanced breast cancer who had progressed on a CDK4/6 inhibitor. The benefit was particularly pronounced in patients with ESR1-mutated tumors, establishing this combination as a promising new treatment strategy for this resistant population. ()
TP53 Y220C hotspot mutation in clinically advanced ovarian carcinoma: Frequency and genomic features. A large-scale genomic analysis revealed that the potentially targetable TP53 Y220C mutation occurs in 2.9% of clinically advanced ovarian carcinomas, making it one of the most frequent tumor types to harbor this alteration. This finding highlights a subset of ovarian cancer patients who may be eligible for novel therapies designed to restore wild-type p53 function, such as Rezatapopt (PC14586). ()
Study design of the phase III ADELA trial of elacestrant with or without everolimus in <i>ESR1</i>-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor. The ADELA trial is a phase III study designed to evaluate the efficacy of elacestrant, both as a monotherapy and in combination with everolimus, for patients with ESR1-mutated, ER+/HER2- advanced breast cancer that has progressed after treatment with a CDK4/6 inhibitor. This study aims to define optimal treatment pathways for this endocrine-resistant patient population. ()
First-line fecal microbiota transplantation for the management of immune checkpoint inhibitor-mediated diarrhea and colitis. A preliminary analysis suggests that first-line fecal microbiota transplantation (FMT) is an effective strategy for managing immune checkpoint inhibitor-mediated diarrhea and colitis, with 76.9% of patients achieving a clinical response. Post-FMT, responders showed increased gut microbial diversity and a reduction in immune cell infiltration, providing a strong rationale for this approach in managing immunotherapy-related toxicities. ()
Multimodal assessment of exceptional responders refines subtyping-directed precision treatment in HR+/HER2- breast cancer. By integrating multi-omic data from the FASCINATE-N trial, this study identified key biological features of exceptional responders within different HR+/HER2- breast cancer subtypes, offering refined therapeutic strategies. For instance, lymphatic vessel infiltration was linked to better immunotherapy outcomes in SNF2 tumors, while DNA repair mutations predicted response to PARP and CDK4/6 inhibitors in the SNF3 subtype, underscoring the value of deep molecular and spatial analysis. ()
5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial. The 5-year follow-up of the PHERGain trial confirms the long-term safety and efficacy of a PET-guided strategy to de-escalate chemotherapy in HER2-positive early breast cancer, with a 92.4% invasive disease-free survival in PET responders who achieved pCR without chemotherapy. Exploratory analysis also showed that circulating tumor DNA (ctDNA) dynamics correlated with pCR rates and long-term outcomes, suggesting ctDNA could further refine treatment individualization. ()
Recurrence Score gene group components and outcomes in the RxPONDER trial (SWOG S1007). An analysis of the RxPONDER trial data revealed that while the overall 21-gene Recurrence Score (RS) was similar across ethnic groups, the underlying gene group components, such as proliferation scores, varied significantly. Tumors from non-Hispanic Black and Hispanic women had higher proliferation scores, suggesting that evaluating specific biological pathways beyond the composite RS may be crucial for understanding outcome disparities and refining risk stratification. ()
The Vanguard Study: Assessing feasibility of conducting randomized trials of novel multi-cancer detection tests. The CSRN Vanguard Study is a large-scale randomized trial designed to establish the feasibility and critical protocol components for evaluating novel blood-based Multi-Cancer Detection (MCD) tests in the US. By randomizing 18,000-24,000 participants to different MCD tests or a control arm, this study will provide essential data to inform the design of a future definitive trial on the public health benefits of these emerging screening technologies. ()
Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer. This study demonstrates that a liquid biopsy platform using cell-free ChIP-sequencing (cfChIP-seq) can noninvasively assess tumor burden and determine the transcriptional subtype (e.g., ASCL1, NEUROD1) of small cell lung cancer (SCLC) directly from plasma. This technology offers a practical tool for real-time monitoring and could enable subtype-informed therapeutic strategies without the need for tissue biopsies. ()
Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial. The addition of atezolizumab to neoadjuvant chemotherapy did not significantly improve event-free survival in the overall population of patients with stage II-III triple-negative breast cancer (TNBC). However, subgroup analyses suggest a potential benefit for patients with clinical lymph node involvement and those with basal-like immune-activated tumors, indicating that biomarker selection will be critical for identifying TNBC patients who may benefit from this approach. ()
A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics. A temporal multi-omics analysis of advanced triple-negative breast cancer (TNBC) patients treated with chemo-immunotherapy identified distinct microenvironment signatures predictive of outcomes. Favorable responses were linked to immune-enriched tumors with organized lymphoid structures, whereas poor outcomes were associated with fibrotic, angiogenic microenvironments, which were further amplified as a resistance mechanism upon treatment. ()
The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy. Preclinical data show that ART6043, a first-in-class, potent inhibitor of DNA polymerase theta (Polθ), effectively abrogates microhomology-mediated end joining and strongly potentiates the efficacy of PARP inhibitors in homologous recombination-deficient (HRD) tumor models. These findings provide a strong rationale for the ongoing phase I/IIa clinical trial combining ART6043 with PARP inhibitors for HRD cancers. ()
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR. In the large EA1181 trial, neoadjuvant taxane, trastuzumab, and pertuzumab (THP) yielded high pCR rates, especially in HER2+/ER- tumors (63.7%). Independent predictors of pCR included low hormone receptor expression, HER2 IHC 3+ status, weekly paclitaxel use, and a high HER2DX pCR score, providing valuable factors for optimizing risk stratification and personalizing treatment for HER2-positive breast cancer. ()
Nivolumab and cabozantinib in people with HIV and advanced solid tumors: a pilot trial and systematic review. A pilot trial demonstrated that the combination of nivolumab and cabozantinib has a manageable safety profile for people living with HIV (PWH) who have advanced solid tumors, without compromising HIV virologic control. The study, which included several patients with Kaposi sarcoma, showed durable disease stabilization in some heavily pretreated participants, supporting larger, dedicated studies of this combination in the PWH population. ()
Serum-based biomarker development for dietary macronutrient densities and their association with breast and colorectal cancer risk in a cohort of postmenopausal females. Using serum metabolomics from the Women's Health Initiative, this study developed biomarker equations for macronutrient intake and found that a higher dietary monounsaturated fatty acid (MUFA) density was associated with an increased risk of colorectal cancer in postmenopausal women. These findings suggest that biomarker-calibrated dietary assessments can provide more reliable insights into diet-cancer relationships than traditional self-reported data. ()
Biomarker-calibrated dietary macronutrient densities and their comparative associations with chronic disease risk in a cohort of postmenopausal females. By using biomarker-calibrated dietary data from the Women's Health Initiative, this study found that higher saturated fatty acid (SFA) density was associated with an increased risk of coronary artery disease and type 2 diabetes, while higher polyunsaturated fatty acid (PUFA) density was linked to an increased risk of breast cancer. These findings refine our understanding of how different macronutrients contribute to chronic disease risk in postmenopausal women. ()
Impact of opioid-free general anesthesia with locoregional blocks during breast cancer surgery on systemic inflammatory response: results from a randomized controlled trial. A randomized trial demonstrated that opioid-free general anesthesia with locoregional blocks significantly reduced the postoperative systemic inflammatory response, as measured by the neutrophil-to-lymphocyte ratio and circulating cytokines, compared to traditional opioid-based anesthesia in patients undergoing breast cancer surgery. This less inflammatory anesthetic approach was also better tolerated, suggesting potential benefits for patient recovery. ()
Impact of remote management using patient-reported outcomes on pain and anxiety after breast biopsy: the BIO-PSY randomized controlled trial. A randomized trial found that remote monitoring with patient-reported outcomes (PROs) after breast biopsy significantly reduced the proportion of patients with clinically significant anxiety, particularly when follow-up involved direct phone contact with a psycho-oncologist. While post-biopsy pain was well-controlled across all groups, the study highlights the value of PRO-based interventions for improving psychological outcomes in routine care. ()
A randomized phase II study of fulvestrant with or without ganetespib in patients with endocrine-resistant metastatic breast cancer. The addition of the HSP90 inhibitor ganetespib to fulvestrant did not improve progression-free survival and increased toxicity in patients with endocrine-resistant, HR-positive metastatic breast cancer. Exploratory genomic analysis suggested that ESR1 mutations and proliferative transcriptional activity contribute to resistance, limiting the efficacy of this combination in a heavily pretreated population. ()
Carbon nanoparticle-Fe (II) complex for ferroptosis therapy in refractory solid tumors: a phase I trial. A first-in-human phase I trial of a novel carbon nanoparticle-Fe (II) complex (CNSI-Fe) demonstrated a favorable safety profile and promising preliminary antitumor activity when delivered intratumorally in patients with refractory solid tumors. The treatment, designed to induce cancer cell ferroptosis, achieved a disease control rate of 84.2%, supporting its advancement into phase II investigations. ()
Prospective comparison of [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer. This prospective study found that post-treatment [68Ga]Ga-FAPI-04 PET imaging showed superior performance in predicting pathologic complete response (pCR) compared to [18F]FDG PET/CT and MRI, particularly for assessing axillary lymph node status in breast cancer patients after neoadjuvant chemotherapy. These results suggest that FAPI-PET could become a valuable tool for more accurate, individualized preoperative planning. ()
Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases. An analysis of patient-reported outcomes (PROs) from the TBCRC 022 trial revealed that gastrointestinal toxicities, particularly diarrhea, were more severe from the patient's perspective than captured by clinician-reported CTCAE grades. This highlights the critical value of incorporating PROs in clinical trials to better understand the patient experience and guide more effective supportive care strategies. ()
EORTC QLQ-C30 symptom components and their functional correlates during adjuvant chemotherapy for early breast cancer: a multivariate analysis. Data from GEICAM/2003-02 study. A multivariate analysis of patient-reported outcomes from the GEICAM/2003-02 trial identified a dominant "general symptom burden" component, anchored by fatigue, that was most strongly correlated with functional decline during adjuvant chemotherapy. This finding suggests that managing fatigue is central to preserving quality of life and that multivariate approaches can offer a more holistic understanding of treatment-related burden. ()
Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial. The final analysis of the IMpassion050 trial confirmed that adding atezolizumab to neoadjuvant and adjuvant standard therapy did not significantly improve event-free or disease-free survival in patients with high-risk HER2-positive early breast cancer. Although numerical trends favored atezolizumab in certain subgroups (e.g., PD-L1-negative, HR-positive), the overall results do not support the addition of atezolizumab in this setting. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in breast cancer updated from 2026-10-01 to 2026-10-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation----1-1
Not Yet Recruiting8413-8-33
Recruiting3334501253146
Available-------
Approved for Marketing-------
Active, Not Recruiting131027-30181
Completed-1111-4
Total5449912654265
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
paclitaxel, [18F]FLT, ribociclib NCT02608216 ACTIVE_NOT_RECRUITING [18F]Fluorothymidine (FLT) PET/CT Imaging in Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 and Weekly Paclitaxel Therapy 2026-11
Abemaciclib, Paclitaxel, Anastrozole, Exemestane, or Letrozole, Fulvestrant, LOXO-783, Imlunestrant NCT05307705 ACTIVE_NOT_RECRUITING A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation 2026-12
Cannabis capsules NCT05969314 ACTIVE_NOT_RECRUITING Phase I Study of Safety and Feasibility of Ayurvedic Oral Cannabis Preparation in the Peri-operative Period in Breast and Oral Cavity Squamous Cell Cancer 2026-12-30
Velzatinib, Cyclosporine, Omeprazole NCT07862114 NOT_YET_RECRUITING A Phase 1 Non-Randomized, Open-Label, Parallel-Group Study to Investigate the Effects of Coadministration of the Proton Pump Inhibitor Omeprazole or the P-gp/BCRP Inhibitor Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Velzatinib in Healthy Participants 2027-01-12
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Tamoxifen, Abemaciclib, Prophylactic Loperamide NCT02747004 COMPLETED A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer 2026-09-09
Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle)., Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle). NCT03330847 ACTIVE_NOT_RECRUITING A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE). 2026-10-09
F-18 16 Alpha-Fluoroestradiol NCT06260033 RECRUITING A Phase II Trial of Stereotactic Body Radiation Therapy and Fluoroestradiol Positron Emission Tomography in Patients With Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer 2026-10-29
paclitaxel albumin-stabilized nanoparticle formulation, carboplatin NCT01525966 ACTIVE_NOT_RECRUITING Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer 2026-11-11
: Pembrolizumab NCT02644369 ACTIVE_NOT_RECRUITING Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation 2026-12
Utidelone Capsule Plus Capecitabine NCT06458413 ACTIVE_NOT_RECRUITING :Single-arm, Phase II Clinical Trial of Utidelone Capsule Plus Capecitabine (CAP) in Patients With Metastatic Breast Cancer 2026-12-30
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Ado-trastuzumab emtansine (T-DM1), Trastuzumab deruxtecan (T-DXd) NCT03529110 COMPLETED A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 2026-08-31
metformin hydrochloride NCT01905046 ACTIVE_NOT_RECRUITING Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women 2026-11
Paclitaxel + Carboplatin, Paclitaxel only NCT03168880 ACTIVE_NOT_RECRUITING A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer 2026-11-30
0.5% lignocaine 60mM NCT01916317 ACTIVE_NOT_RECRUITING Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer 2026-12-31
Systemic Chemotherapy, Exemestane, Anastrozole, Letrozole, Tamoxifen Citrate NCT01272037 ACTIVE_NOT_RECRUITING A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer 2027-01-08
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.